By Kelly Cloonan
FibroGen has terminated its previous exclusive license and option agreement with HiFiBiO and agreed to license certain intellectual property to the company.
Under the terms of the new agreement, FibroGen has licensed its anti-CCR8 and anti-Gal-9 intellectual property to HiFiBiO, the biopharmaceutical company said Friday.
If HiFiBiO sublicenses either asset, FibroGen is eligible to receive a mid single-digit to low double-digit share of HiFiBiO's license revenues and a low double-digit share of commercial royalties, the company said.
If HiFiBiO commercializes either asset, FibroGen could receive single digit royalties based on worldwide net sales.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
June 13, 2025 16:47 ET (20:47 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.